PMID- 32528476
OWN - NLM
STAT- MEDLINE
DCOM- 20210329
LR  - 20210329
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 11
DP  - 2020
TI  - Myeloid-Derived Suppressor Cells in the Context of Allogeneic Hematopoietic Stem 
      Cell Transplantation.
PG  - 989
LID - 10.3389/fimmu.2020.00989 [doi]
LID - 989
AB  - Myeloid-derived suppressor cells (MDSCs) are innate immune cells that acquire the 
      capacity to suppress adaptive immune responses. In the context of allogeneic 
      hematopoietic stem cell transplantation (allo-HSCT), MDSCs (in the donor graft 
      and in the recipient, after allo-HSCT) might mediate immune suppression through 
      multiple mechanisms. However, it remains unclear how MDSCs can be distinguished 
      from their normal myeloid counterparts in the hematopoietic stem cell donor graft 
      and during immune reconstitution after allo-HSCT in the recipient. Our ability to 
      understand their exact role in allo-HSCT is limited by the absence of a specific 
      gene signature or surface markers for identifying MDSCs among myeloid cells and 
      by their plasticity in different microenvironments. According to various studies, 
      MDSCs might induce transplant tolerance and control graft vs. host disease 
      (GVHD), but their impact on the graft vs. tumor effect (GVT) is not fully 
      understood. In fact, we know that MDSCs commonly expand in patients with cancer, 
      and they are thought to promote hematological malignancy progression. However, 
      little is known about whether depleting them might be an effective strategy for 
      enhancing GVT effects. Here, we review data published over the past 40 years on 
      allo-HSCT to delineate the different MDSC subsets, and their abilities to induce 
      transplant tolerance and preserve the GVT effect. This review will provide a 
      basis for determining whether one MDSC subset might be proposed as the most 
      appropriate candidate for cellular therapies, due to its ability to modulate 
      GVHD.
CI  - Copyright (c) 2020 D'Aveni, Notarantonio, Bertrand, Boulange, Pochon and Rubio.
FAU - D'Aveni, Maud
AU  - D'Aveni M
AD  - Hematology Department, CHRU Nancy, Universite de Lorraine, Nancy, France.
AD  - Universite de Lorraine, UMR 7365 CNRS, IMoPA, Nancy, France.
FAU - Notarantonio, Anne B
AU  - Notarantonio AB
AD  - Hematology Department, CHRU Nancy, Universite de Lorraine, Nancy, France.
AD  - Universite de Lorraine, UMR 7365 CNRS, IMoPA, Nancy, France.
FAU - Bertrand, Allan
AU  - Bertrand A
AD  - Universite de Lorraine, UMR 7365 CNRS, IMoPA, Nancy, France.
FAU - Boulange, Laura
AU  - Boulange L
AD  - Universite de Lorraine, UMR 7365 CNRS, IMoPA, Nancy, France.
FAU - Pochon, Cecile
AU  - Pochon C
AD  - Hematology Department, CHRU Nancy, Universite de Lorraine, Nancy, France.
AD  - Universite de Lorraine, UMR 7365 CNRS, IMoPA, Nancy, France.
FAU - Rubio, Marie T
AU  - Rubio MT
AD  - Hematology Department, CHRU Nancy, Universite de Lorraine, Nancy, France.
AD  - Universite de Lorraine, UMR 7365 CNRS, IMoPA, Nancy, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200522
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
SB  - IM
MH  - Animals
MH  - Graft Rejection/immunology/metabolism/*prevention & control
MH  - *Graft Survival
MH  - Graft vs Host Disease/immunology/metabolism/*prevention & control
MH  - Graft vs Tumor Effect
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Humans
MH  - Myeloid-Derived Suppressor Cells/*immunology/metabolism
MH  - Phenotype
MH  - Risk Factors
MH  - *Transplantation Tolerance
MH  - Transplantation, Homologous
MH  - Treatment Outcome
PMC - PMC7256196
OTO - NOTNLM
OT  - GvH disease
OT  - GvT
OT  - allogeneic stem cell transplanation
OT  - cellular therapy
OT  - myeloid-derived suppressor cell
EDAT- 2020/06/13 06:00
MHDA- 2021/03/30 06:00
PMCR- 2020/01/01
CRDT- 2020/06/13 06:00
PHST- 2020/03/05 00:00 [received]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/06/13 06:00 [entrez]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2021/03/30 06:00 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2020.00989 [doi]
PST - epublish
SO  - Front Immunol. 2020 May 22;11:989. doi: 10.3389/fimmu.2020.00989. eCollection 
      2020.